SEC Form 4 · accession 0001104659-17-033537
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Harrison Talbot
Director
Period of report
Feb 16, 2017
Accepted (ET)
May 17, 2017 · 7:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F2 | Feb 16, 2017 | M | 502 | — | A | 3,351 | D | |
| Common SharesF1,F2 | Feb 16, 2017 | M | 155 | — | A | 3,506 | D | |
| Common SharesF1,F2 | Feb 16, 2017 | M | 578 | — | A | 4,084 | D | |
| Common SharesF3,F4 | May 15, 2017 | S | 50 | $101.50 | D | 4,034 | D | |
| Common SharesF3,F5 | May 16, 2017 | S | 50 | $102.268 | D | 3,984 | D | |
| Common SharesF3,F6 | May 16, 2017 | S | 100 | $103.00 | D | 3,884 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F2,F7 | — | Feb 16, 2017 | M | 502 | D | — | Sep 27, 2017 | Common Shares | 502 | 0 | D |
| Stock OptionF1,F2,F8 | — | Feb 16, 2017 | M | 155 | D | — | Sep 27, 2017 | Common Shares | 155 | 0 | D |
| Stock OptionF1,F2,F9 | — | Feb 16, 2017 | M | 578 | D | — | Sep 27, 2017 | Common Shares | 578 | 135 | D |
Explanation of responses
- F1This transaction is being reported late due to an administrative oversight.
- F2The exercise price was Euro 6.72 per common share.
- F3The common shares whose sale is reported on this line are represented by American Depositary Shares ("ADSs"). Each ADS represents one tenth (1/10) of a common share of Nabriva Therapeutics AG. The reporting person may hold both common shares and ADSs representing common shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of common shares.
- F4The price of $101.50 per common share was derived from the sale price on May 15, 2017, of $10.15 per ADS, multiplied by ten.
- F5The price of $102.268 per common share was derived from the sale price on May 16, 2017, of $10.2268 per ADS, multiplied by ten.
- F6The price of $103.00 per common share was derived from the sale price on May 16, 2017, of $10.30 per ADS, multiplied by ten.
- F7This option was granted on June 12, 2009 and is fully vested.
- F8This option was granted on January 29, 2010 and is fully vested.
- F9This option was granted on August 31, 2014. Vesting began on August 31, 2014 and ends on September 30, 2017. Twenty-five percent (25%) of the option vested on December 31, 2014, a further twenty-five percent (25%) of the options vested on December 31, 2015, and the remaining fifty percent (50%) vests on a monthly pro-rata basis over the remaining vesting period.